BOSTON — Compared with 17,800 patients starting new inhaled COPD maintenance therapy in 2016, 32,558 patients started a new inhaled treatment in 2022, according to a presentation at the CHEST ...

Eligible patients had COPD, were ages 40 or older, and were new initiators of these inhalers from 2021 to 2023. They were allowed to be on monotherapy or dual therapy during the year before cohort ...

Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...

New Study Shows Promising Results for COPD Treatment Nov. 20 ... have found that dual bronchodilators -- long-lasting inhalers that relax the airways and make it easier to breathe -- do little ...

After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

Individuals with early-onset COPD and rapidly progressive pre-COPD frequently have a decades-long history of impaired ...

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...

AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...

Jan. 13, 2025 (GLOBE NEWSWIRE) -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company dedicated to developing inhaled medicines, today announced the commencement of a new ...

"We are proud to continue advancing our asthma and COPD inhaled drug program, achieving key clinical development milestones on schedule,” said Xian-Ming Zeng, Ph.D., CEO of Transpire Bio. "These ...